Cargando…
High mobility group box-1 and its clinical value in breast cancer
BACKGROUND: High mobility group box-1 (HMGB1) is a factor regulating malignant tumorigenesis, proliferation, and metastasis, and is associated with poor clinical pathology in various human cancers. We investigated the differential concentrations of HMGB1 in tissues and sera, and their clinical value...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334343/ https://www.ncbi.nlm.nih.gov/pubmed/25709474 http://dx.doi.org/10.2147/OTT.S73366 |
_version_ | 1782358175497846784 |
---|---|
author | Sun, Shanping Zhang, Wei Cui, Zhaoqing Chen, Qi Xie, Panpan Zhou, Changxin Liu, Baoguo Peng, Xiangeng Zhang, Yang |
author_facet | Sun, Shanping Zhang, Wei Cui, Zhaoqing Chen, Qi Xie, Panpan Zhou, Changxin Liu, Baoguo Peng, Xiangeng Zhang, Yang |
author_sort | Sun, Shanping |
collection | PubMed |
description | BACKGROUND: High mobility group box-1 (HMGB1) is a factor regulating malignant tumorigenesis, proliferation, and metastasis, and is associated with poor clinical pathology in various human cancers. We investigated the differential concentrations of HMGB1 in tissues and sera, and their clinical value for diagnosis in patients with breast cancer, benign breast disease, and healthy individuals. METHODS: HMGB1 levels in tumor tissues, adjacent normal tissues, and benign breast disease tissues was detected via immunohistochemistry. Serum HMGB1 was measured using an enzyme-linked immunosorbent assay in 56 patients with breast cancer, 25 patients with benign breast disease, and 30 healthy control subjects. The clinicopathological features of the patients were compared. Tissues were evaluated histopathologically by pathologists. RESULTS: HMGB1 levels in the tissues and sera of patients with breast cancer were significantly higher than those in patients with benign breast disease or normal individuals. The 56 cancer patients were classified as having high tissue HMGB1 levels (n=41) or low tissue HMGB1 levels (n=15), but the corresponsive serum HMGB1 in these two groups was not significantly different. HMGB1 levels in breast cancer tissues significantly correlated with differentiation grade, lymphatic metastasis, and tumor-node-metastasis stage, but not patient age, tumor size, or HER-2/neu expression; no association between serum HMGB1 levels and these clinicopathological parameters was found. The sensitivity and specificity of tissue HMGB1 levels for the diagnosis of breast cancer were 73.21% and 84.00%, respectively, while positive and negative predictive values were 91.11% and 58.33%. CONCLUSION: HMGB1 might be involved in the development and progression of breast cancer and could be a supportive diagnostic marker for breast cancer. Serum HMGB1 could be a useful serological biomarker for diagnosis and screening of breast cancer. |
format | Online Article Text |
id | pubmed-4334343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43343432015-02-23 High mobility group box-1 and its clinical value in breast cancer Sun, Shanping Zhang, Wei Cui, Zhaoqing Chen, Qi Xie, Panpan Zhou, Changxin Liu, Baoguo Peng, Xiangeng Zhang, Yang Onco Targets Ther Original Research BACKGROUND: High mobility group box-1 (HMGB1) is a factor regulating malignant tumorigenesis, proliferation, and metastasis, and is associated with poor clinical pathology in various human cancers. We investigated the differential concentrations of HMGB1 in tissues and sera, and their clinical value for diagnosis in patients with breast cancer, benign breast disease, and healthy individuals. METHODS: HMGB1 levels in tumor tissues, adjacent normal tissues, and benign breast disease tissues was detected via immunohistochemistry. Serum HMGB1 was measured using an enzyme-linked immunosorbent assay in 56 patients with breast cancer, 25 patients with benign breast disease, and 30 healthy control subjects. The clinicopathological features of the patients were compared. Tissues were evaluated histopathologically by pathologists. RESULTS: HMGB1 levels in the tissues and sera of patients with breast cancer were significantly higher than those in patients with benign breast disease or normal individuals. The 56 cancer patients were classified as having high tissue HMGB1 levels (n=41) or low tissue HMGB1 levels (n=15), but the corresponsive serum HMGB1 in these two groups was not significantly different. HMGB1 levels in breast cancer tissues significantly correlated with differentiation grade, lymphatic metastasis, and tumor-node-metastasis stage, but not patient age, tumor size, or HER-2/neu expression; no association between serum HMGB1 levels and these clinicopathological parameters was found. The sensitivity and specificity of tissue HMGB1 levels for the diagnosis of breast cancer were 73.21% and 84.00%, respectively, while positive and negative predictive values were 91.11% and 58.33%. CONCLUSION: HMGB1 might be involved in the development and progression of breast cancer and could be a supportive diagnostic marker for breast cancer. Serum HMGB1 could be a useful serological biomarker for diagnosis and screening of breast cancer. Dove Medical Press 2015-02-12 /pmc/articles/PMC4334343/ /pubmed/25709474 http://dx.doi.org/10.2147/OTT.S73366 Text en © 2015 Sun et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Sun, Shanping Zhang, Wei Cui, Zhaoqing Chen, Qi Xie, Panpan Zhou, Changxin Liu, Baoguo Peng, Xiangeng Zhang, Yang High mobility group box-1 and its clinical value in breast cancer |
title | High mobility group box-1 and its clinical value in breast cancer |
title_full | High mobility group box-1 and its clinical value in breast cancer |
title_fullStr | High mobility group box-1 and its clinical value in breast cancer |
title_full_unstemmed | High mobility group box-1 and its clinical value in breast cancer |
title_short | High mobility group box-1 and its clinical value in breast cancer |
title_sort | high mobility group box-1 and its clinical value in breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334343/ https://www.ncbi.nlm.nih.gov/pubmed/25709474 http://dx.doi.org/10.2147/OTT.S73366 |
work_keys_str_mv | AT sunshanping highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT zhangwei highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT cuizhaoqing highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT chenqi highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT xiepanpan highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT zhouchangxin highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT liubaoguo highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT pengxiangeng highmobilitygroupbox1anditsclinicalvalueinbreastcancer AT zhangyang highmobilitygroupbox1anditsclinicalvalueinbreastcancer |